Condition
Abnormal Glucose Tolerance
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (3)
Trial Status
Unknown1
Not Yet Recruiting1
Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07688070Phase 2Not Yet Recruiting
Verapamil Effect in Cystic Fibrosis-related Dysglycemia
NCT04731272Phase 2Recruiting
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
NCT01773707Phase 2CompletedPrimary
CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1
NCT04490460Not ApplicableUnknownPrimary
Effects on Glycemic Control of WBF-0031 in Subjects With Abnormal Glucose Tolerance
Showing all 4 trials